# Novo Nordisk: 3 Key Takeaways for Long-Term Investors

> Novo Nordisk's Wegovy pill expands to 20+ markets by mid-2027, with 1.3M new patients and CagriSema showing 12.4% weight loss.
- Title: Novo Nordisk: 3 Key Takeaways for Long-Term Investors
- Summary: Novo Nordisk's Wegovy pill expands to 20+ markets by mid-2027, with 1.3M new patients and CagriSema showing 12.4% weight loss. Novo Nordisk added 1.3 million…
- Keywords: novo nordisk, wegovy, cagrisema, weight loss, diabetes, obesity, glp-1, pharmaceuticals, The Motley Fool
- Source: The Motley Fool — https://fool.com/earnings/takeaways/2026/11/04/novo-nordisk-3-key-takeaways-for-long-term-investors
- Author: The Motley Fool Team
- Published: 2026-11-05T01:55:55+00:00
- Read time: 1 min
- Topics: novo nordisk, wegovy, cagrisema, weight loss, diabetes, obesity, glp-1, pharmaceuticals, finance, money
## Wegovy Pill Expansion
Wegovy pill will reach over 20 markets by mid-2027.

> By first half of 2027, we now expect Wegovy pill to be available in more than 20 markets.
## Patient Volume Recovery
Novo Nordisk added 1.3 million patients in the third quarter.

> After a flat start to the year, patient additions accelerated across both diabetes and obesity divisions.
## CagriSema Trial Results
CagriSema delivered 12.4% weight loss in a 60-week trial.

> At one milligram of each component, CagriSema demonstrated superior weight loss of 12.4% compared with 9.1% for tirzepatide
## Long-Term Strategy
Novo Nordisk focuses on innovation and patient impact for sustained market leadership.

> Long-term performance hinges on maintaining market leadership while navigating patent expirations and contract pricing dynamics across key geographies.
## Key takeaway

Novo Nordisk added 1.3 million patients in Q3, Wegovy reaches 20+ markets by mid-2027, and CagriSema delivers 12.4% weight loss in trials.